The global Glucokinase Market Comprehensive Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments -By Type (LY-2608204, Sinogliatin, AM-9514, TMG-123, TTP-99, Others), By Application (Metabolic Disorder, Obesity, Diabetes, Others)
In 2024, the Glucokinase market is witnessing robust growth, driven by the rising demand for enzymes in pharmaceutical and biotechnological applications. Glucokinase, an enzyme that plays a crucial role in glucose metabolism, is used in diabetes research and drug development. The market benefits from advancements in enzyme production and biotechnological research, the growing trend of personalized medicine, and the expansion of the global pharmaceutical sector. Additionally, the increasing prevalence of diabetes and the need for innovative treatments are contributing to market growth.
The market report analyses the leading companies in the industry including Amgen Inc, Eli Lilly and Company, Ligand Pharmaceuticals Incorporated, Merck & Co., Inc., Poxel SA, Teijin Pharma Limited, vTv Therapeutics Inc, Yuhan Corporation, and Others.
The most prominent trend in the Glucokinase Market is the increasing research and development in diabetes management. As the prevalence of diabetes continues to rise, there is a growing focus on finding innovative solutions to manage and treat the condition. Glucokinase, an enzyme that plays a crucial role in glucose metabolism, is gaining attention for its potential in developing new diabetes therapies.
The key driver of the Glucokinase Market is the growth in diabetes prevalence. As more people are diagnosed with diabetes, there is a higher demand for effective treatments and management strategies. This driver is supported by the increasing incidence of lifestyle-related conditions such as obesity and metabolic syndrome, which contribute to the rising rates of diabetes, driving market growth for glucokinase research and applications.
A significant opportunity in the Glucokinase Market lies in the development of targeted diabetes therapies. By focusing on the role of glucokinase in regulating blood sugar levels, companies can create innovative treatments that offer better glucose control and fewer side effects. Collaborating with research institutions and investing in clinical trials can help bring new glucokinase-based therapies to market, addressing the growing need for advanced diabetes treatments.
LY-2608204 is identified as the largest segment within the Glucokinase market. This particular type has garnered significant attention and adoption due to its efficacy in targeting glucokinase, an enzyme crucial in glucose metabolism regulation. LY-2608204 and similar compounds are being extensively studied and developed for their potential therapeutic benefits in managing diabetes mellitus and related metabolic disorders. The segment's dominance is reinforced by ongoing clinical trials and research initiatives aimed at exploring the compound's safety, efficacy, and mechanism of action in controlling blood glucose levels. Pharmaceutical companies are investing in the development of LY-2608204-based therapies to address the growing global burden of diabetes and the increasing demand for innovative treatment options that offer better glucose control with minimal side effects. As advancements in biotechnology and drug development continue to accelerate, LY-2608204 holds promise as a leading player in shaping the future of glucokinase-targeted therapies, catering to the needs of diabetic patients worldwide.
The Diabetes segment is projected to be the fastest-growing application within the Glucokinase market through 2032. This growth is driven by the rising prevalence of diabetes globally, coupled with the increasing demand for effective therapies that can provide better management of blood glucose levels. Glucokinase plays a pivotal role in glucose homeostasis, and pharmaceutical companies are focusing on developing glucokinase activators like LY-2608204 to enhance insulin secretion and improve glycemic control in diabetic patients. The Diabetes segment's expansion is further supported by advancements in precision medicine and personalized treatment approaches, tailoring therapies to individual patient needs. Clinical trials and research efforts continue to validate the efficacy and safety profiles of glucokinase activators, paving the way for potential regulatory approvals and market penetration. As healthcare systems prioritize the management and prevention of diabetes-related complications, the Diabetes segment in the Glucokinase market presents substantial growth opportunities for biopharmaceutical companies aiming to address unmet medical needs and improve patient outcomes.
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Amgen Inc
Eli Lilly and Company
Ligand Pharmaceuticals Incorporated
Merck & Co., Inc.
Poxel SA
Teijin Pharma Limited
vTv Therapeutics Inc
Yuhan Corporation
*- List Not Exhaustive
Chapter 1. TABLE OF CONTENTS
Chapter 2. Introduction to Glucokinase Market
2.1. Market Overview
2.2. Key Statistics and Report Highlights
2.3. Scope of the Comprehensive Study
2.3.1. Market Definition
2.3.2 Countries and Regions Covered
2.3.3 Research Objective
2.3.4 Units, Currency, and Conversions
2.3.5 Industry Value Chain
2.4. Key Market Segments
2.5. Key Companies
2.6. Study Period
Chapter 3. Strategic Analysis Review
3.1. Glucokinase Pricing Analysis and Forecast
3.2. Porter’s Five Forces
3.3. Market Ecosystem
3.4. SWOT Analysis
3.5. Regulatory Scenario
3.3. Effects of Inflation, Russia-Ukraine War, moderating economic growth, and other macroeconomic factors
Chapter 4. Competitive Landscape
4.1. Market Share Analysis
4.1.1. Global Glucokinase Market Share by Company, 2023
4.1.2. Product Offerings of Leading Glucokinase Companies
4.2. Market Entropy
4.2.1. New Product Launches in the Industry
4.2.2. Mergers, Acquisitions, Joint ventures, and Partnerships
4.3. Key Strategies and Best Practices
Chapter 5. Global Market Projections: Best, Reference, and Low Case Scenarios
5.1. Growth Analysis- Case Scenario Definitions
5.2. Low Growth Case Scenario Forecasts
5.3. Reference Growth Case Scenario Forecasts
5.4. High Growth Case Scenario Forecasts
Chapter 6. Market Dynamics
6.1. Glucokinase Market Drivers
6.2. Glucokinase Market Challenges
6.6. Glucokinase Market Opportunities
6.4. Glucokinase Market Trends
Chapter 7. Global Glucokinase Market Outlook Trends
7.1. Global Glucokinase Revenue (USD Million) and CAGR (%) by Type (2021-2032)
7.2. Global Glucokinase Revenue (USD Million) and CAGR (%) by Application (2021-2032)
7.3. Global Glucokinase Revenue (USD Million) and CAGR (%) by Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Chapter 8. Global Glucokinase Regional Analysis and Outlook
8.1. Global Glucokinase Revenue (USD Million) By Regions (2021- 2032)
8.2. North America Glucokinase Revenue (USD Million) by Country (2021-2032)
8.2.1. United States Glucokinase Regional Analysis and Outlook
8.2.2. Canada Glucokinase Regional Analysis and Outlook
8.2.3. Mexico Glucokinase Regional Analysis and Outlook
8.3. Europe Glucokinase Revenue (USD Million), by Country (2021-2032)
8.3.1. Germany Glucokinase Regional Analysis and Outlook
8.3.2. France Glucokinase Regional Analysis and Outlook
8.3.3. United Kingdom Glucokinase Regional Analysis and Outlook
8.3.4. Spain Glucokinase Regional Analysis and Outlook
8.3.5. Italy Glucokinase Regional Analysis and Outlook
8.3.6. Russia Glucokinase Regional Analysis and Outlook
8.3.7. Rest of Europe Glucokinase Regional Analysis and Outlook
8.4. Asia Pacific Glucokinase Revenue (USD Million) by Country (2021-2032)
8.4.1. China Glucokinase Regional Analysis and Outlook
8.4.2. Japan Glucokinase Regional Analysis and Outlook
8.4.3. India Glucokinase Regional Analysis and Outlook
8.4.4. South Korea Glucokinase Regional Analysis and Outlook
8.4.5. Australia Glucokinase Regional Analysis and Outlook
8.4.6. South East Asia Glucokinase Regional Analysis and Outlook
8.4.7. Rest of Asia Pacific Glucokinase Regional Analysis and Outlook
8.5. South America Glucokinase Revenue (USD Million), by Country (2021-2032)
8.5.1. Brazil Glucokinase Regional Analysis and Outlook
8.5.2. Argentina Glucokinase Regional Analysis and Outlook
8.5.3. Rest of South America Glucokinase Regional Analysis and Outlook
8.6. Middle East and Africa Glucokinase Revenue (USD Million) by Country (2021-2032)
8.6.1. Middle East Glucokinase Regional Analysis and Outlook
8.6.2. Africa Glucokinase Regional Analysis and Outlook
Chapter 9. North America Glucokinase Analysis and Outlook
9.1. North America Glucokinase Revenue (USD Million) by Segments (2021-2032)
9.1.1. North America Glucokinase Revenue (USD Million) by Type (2021-2032)
9.1.2. North America Glucokinase Revenue (USD Million) by Application (2021-2032)
9.1.3. North America Glucokinase Revenue (USD Million) by Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Chapter 10. Europe Glucokinase Analysis and Outlook
10.1. Europe Glucokinase Revenue (USD Million), by Segments (USD Million) (2021-2032)
10.1.1. Europe Glucokinase Revenue (USD Million) by Type (2021-2032)
10.1.2. Europe Glucokinase Revenue (USD Million) by Application (2021-2032)
10.1.3. Europe Glucokinase Revenue (USD Million) by Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Chapter 11. Asia Pacific Glucokinase Analysis and Outlook
11.1. Asia Pacific Glucokinase Revenue (USD Million), and Revenue (USD Million) by Segments (2021-2032)
11.1.1. Asia Pacific Glucokinase Revenue (USD Million) by Type (2021-2032)
11.1.2. Asia Pacific Glucokinase Revenue (USD Million) by Application (2021-2032)
11.1.3. Asia Pacific Glucokinase Revenue (USD Million) by Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Chapter 12. South America Glucokinase Analysis and Outlook
12.1. South America Glucokinase Revenue (USD Million), by Segments (2021-2032)
12.1.1. South America Glucokinase Revenue (USD Million) by Type (2021-2032)
12.1.2. South America Glucokinase Revenue (USD Million) by Application (2021-2032)
12.1.3. South America Glucokinase Revenue (USD Million) by Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Chapter 13. Middle East and Africa Glucokinase Analysis and Outlook
13.1. Middle East and Africa Glucokinase Revenue (USD Million), by Segments (2021-2032)
13.1.1. Middle East and Africa Glucokinase Revenue (USD Million) by Type (2021-2032)
13.1.2. Middle East and Africa Glucokinase Revenue (USD Million) by Application (2021-2032)
13.1.3. Middle East and Africa Glucokinase Revenue (USD Million) by Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Chapter 14. Glucokinase Company Profiles
14.1 Business Overview
14.2 Product Profiles
14.3 SWOT Profiles
14.5 Recent Developments
14.6 Financial Profile
List of Companies
Amgen Inc
Eli Lilly and Company
Ligand Pharmaceuticals Incorporated
Merck & Co., Inc.
Poxel SA
Teijin Pharma Limited
vTv Therapeutics Inc
Yuhan Corporation
15. Methodology and Data Sources
15.1 Customization Offerings
15.2 Subscription Services
15.3 Related Reports
15.4 Publisher Expertise
LIST OF TABLES
Table 1 Market Segmentation Analysis
Table 2 Global Glucokinase Market Share of Leading Companies, 2023
Table 3 Product Offerings of Leading Companies
Table 4 Low Growth Scenario Forecasts
Table 5 Reference Case Growth Scenario
Table 6 High Growth Case Scenario
Table 7 Global Glucokinase Revenue (USD Million) And CAGR (%) By Type (2021-2032)
Table 8 Global Glucokinase Revenue (USD Million) And CAGR (%) By Application (2021-2032)
Table 9 Global Glucokinase Revenue (USD Million) And CAGR (%) By Product (2021-2032)
Table 10 Global Glucokinase Market Revenue (USD Million) By Regions (2021-2032)
Table 11 Global Glucokinase Market Share (%) By Regions (2021-2032)
Table 12 North America Glucokinase Revenue (USD Million) By Country (2021-2032)
Table 13 Europe Glucokinase Revenue (USD Million) By Country (2021-2032)
Table 14 Asia Pacific Glucokinase Revenue (USD Million) By Country (2021-2032)
Table 15 South America Glucokinase Revenue (USD Million) By Country (2021-2032)
Table 16 Middle East and Africa Glucokinase Revenue (USD Million) By Region (2021-2032)
Table 17 North America Glucokinase Revenue (USD Million) By Type (2021-2032)
Table 18 North America Glucokinase Revenue (USD Million) By Application (2021-2032)
Table 19 North America Glucokinase Revenue (USD Million) By Product (2021-2032)
Table 20 Europe Glucokinase Revenue (USD Million) By Type (2021-2032)
Table 21 Europe Glucokinase Revenue (USD Million) By Application (2021-2032)
Table 22 Europe Glucokinase Revenue (USD Million) By Product (2021-2032)
Table 23 Asia Pacific Glucokinase Revenue (USD Million) By Type (2021-2032)
Table 24 Asia Pacific Glucokinase Revenue (USD Million) By Application (2021-2032)
Table 25 Asia Pacific Glucokinase Revenue (USD Million) By Product (2021-2032)
Table 26 South America Glucokinase Revenue (USD Million) By Type (2021-2032)
Table 27 South America Glucokinase Revenue (USD Million) By Application (2021-2032)
Table 28 South America Glucokinase Revenue (USD Million) By Product (2021-2032)
Table 29 Middle East and Africa Glucokinase Revenue (USD Million) By Type (2021-2032)
Table 30 Middle East and Africa Glucokinase Revenue (USD Million) By Application (2021-2032)
Table 31 Middle East and Africa Glucokinase Revenue (USD Million) By Product (2021-2032)
LIST OF FIGURES
Figure 1. Market Scope
Figure 2. Pricing Forecasts Per Unit, 2023- 2032
Figure 3. Porter’s Five Forces
Figure 4. Global Glucokinase Market Revenue (USD Million) By Regions (2021-2032)
Figure 5. Global Glucokinase Market Share (%) By Regions (2023)
Figure 6. North America Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 7. United States Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 8. Canada Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 9. Mexico Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 10. Europe Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 11. Germany Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 12. France Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 13. United Kingdom Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 14. Spain Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 15. Italy Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 16. Russia Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 17. Rest of Europe Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 11. Asia Pacific Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 12. China Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 13. Japan Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 14. India Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 15. South Korea Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 16. Australia Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 17. South East Asia Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 18. South America Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 19. Brazil Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 20. Argentina Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 21. Rest of Asia Pacific Glucokinase Revenue (USD Million) By Country (2021-2032)
Figure 22. Middle East and Africa Glucokinase Revenue (USD Million) By Region (2021-2032)
Figure 23. Saudi Arabia Glucokinase Revenue (USD Million) By Region (2021-2032)
Figure 24. The UAE Glucokinase Revenue (USD Million) By Region (2021-2032)
Figure 25. Rest of Middle East Glucokinase Revenue (USD Million) By Region (2021-2032)
Figure 26. South Africa Glucokinase Revenue (USD Million) By Region (2021-2032)
Figure 27. Africa Glucokinase Revenue (USD Million) By Region (2021-2032)
Figure 28. North America Glucokinase Revenue (USD Million) By Type (2021-2032)
Figure 29. North America Glucokinase Revenue (USD Million) By Application (2021-2032)
Figure 30. North America Glucokinase Revenue (USD Million) By Product (2021-2032)
Figure 31. Europe Glucokinase Revenue (USD Million) By Type (2021-2032)
Figure 32. Europe Glucokinase Revenue (USD Million) By Application (2021-2032)
Figure 33. Europe Glucokinase Revenue (USD Million) By Product (2021-2032)
Figure 34. Asia Pacific Glucokinase Revenue (USD Million) By Type (2021-2032)
Figure 35. Asia Pacific Glucokinase Revenue (USD Million) By Application (2021-2032)
Figure 36. Asia Pacific Glucokinase Revenue (USD Million) By Product (2021-2032)
Figure 37. South America Glucokinase Revenue (USD Million) By Type (2021-2032)
Figure 38. South America Glucokinase Revenue (USD Million) By Application (2021-2032)
Figure 39. South America Glucokinase Revenue (USD Million) By Product (2021-2032)
Figure 40. Middle East and Africa Glucokinase Revenue (USD Million) By Type (2021-2032)
Figure 41. Middle East and Africa Glucokinase Revenue (USD Million) By Application (2021-2032)
Figure 42. Middle East and Africa Glucokinase Revenue (USD Million) By Product (2021-2032)
By Type
LY-2608204
Sinogliatin
AM-9514
TMG-123
TTP-99
Others
By Application
Metabolic Disorder
Obesity
Diabetes
Others
Countries Analyzed
North America (US, Canada, Mexico)
Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, South East Asia, Rest of Asia)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Global Glucokinase Market Size is valued at $812.3 Million in 2024 and is forecast to register a growth rate (CAGR) of 11.9% to reach $1996.9 Million by 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Amgen Inc, Eli Lilly and Company, Ligand Pharmaceuticals Incorporated, Merck & Co., Inc., Poxel SA, Teijin Pharma Limited, vTv Therapeutics Inc, Yuhan Corporation
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2032; Currency: Revenue (USD); Volume